News Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy Heartseed & Novo Nordisk say a patient has been successfully dosed with cell therapy HS-001.
News Novo Nordisk crowns cell therapy pipeline with $598m Heartse... Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed.
News Patient organisations 'too influenced by corporate funders' Researchers have called for action to safeguard the independence of patient advocacy organisations as they increasingly rely on pharma funding.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
